Amrize 10-Q: Q3 EPS $1.02, Free Cash Flow Negative $551M, Buybacks Reach $600M
AMRZ sits 16% above its 52-week low of $35.785 on elevated volume (2.5× avg).
Summary
Amrize's Q3 10-Q confirms $1.02 diluted EPS on $3.77 billion of revenue, but shows nine-month free cash flow of negative $551 million and cash down to $299 million after $750 million of buybacks and $364 million of dividends.
Key Events · Earnings and Guidance · AMRZ
-
Q3 EPS $1.02, Revenue Up 2.2%
Third-quarter revenue rose 2.2% to $3,771 million, and net income attributable to the company was $559 million, or $1.02 diluted per share, versus $0.98 a year earlier.
-
Free Cash Flow Negative $551M
Nine-month operating cash flow of $222 million against $786 million of capex produced negative $551 million of free cash flow, versus negative $186 million in the prior-year period.
-
Cash Falls to $299M, $904M Commercial Paper
Cash and equivalents dropped from $1,922 million at December 31, 2025 to $299 million, with $904 million outstanding under the commercial paper program at a 4.21% weighted average rate.
-
$600M of Buybacks in Q3
The company repurchased 13,058,862 shares in the quarter for $600 million (July at $50.85, August at $46.75, September at $40.86), leaving $0.2 billion of the $1.0 billion authorization.
Analysis · AMRZ · Manufacturing
The headline numbers were already out on October 28, but the full 10-Q fills in what the 8-K did not. Nine-month operating cash flow of just $222 million against $786 million of capex left free cash flow at negative $551 million, and cash on hand fell from $1,922 million to $299 million. That drawdown was funded partly by $904 million of commercial paper at a 4.21% weighted average rate and partly by $750 million of buybacks plus $364 million of dividends — a capital-return program running while the balance sheet thins. Building Envelope is the weak spot: segment Adjusted EBITDA fell 14.6% in the quarter and 14.8% year-to-date on freight and raw material costs, the cost pressure behind the guidance cut. The filing also restates prior periods (nine-month 2025 net income down $22 million) and repeats that disclosure controls were not effective at quarter-end because of the previously reported material weakness — a governance overhang that matters more, not less, when the company is simultaneously revising numbers.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRZ was trading at $41.61 on NYSE in the Manufacturing sector, with a market capitalization of approximately $22.8B. The 52-week trading range was $35.79 to $65.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.